Furthermore, in the subpopulation with very high CLDN18.2 expression (≥ 2+ intensity in ≥70% tumor cells), efficacy was more pronounced (mOS 9 vs. 16.7 mo; HR 0.45; p < .001). Here, CLDN18 is linked to neoplasm.